Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID.

AGC Biologics Partners with Quell Therapeutics to Advance T-Regulatory Cell Therapies for Immune Disorders AGC Biologics, your friendly CDMO expert, today announced a partnership with Quell ...

COPENHAGEN, Denmark & CHIBA, Japan, May 06, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage ...

AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease" Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms ...

SEATTLE & MILAN--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a partnership with Quell Therapeutics (“Quell”), a clinical-stage biotechnology company pioneering ...

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and ...